Olive AI
Olive was a healthcare RPA-and-AI company that hit a $4B valuation in 2021 after raising over $900M from General Catalyst, Tiger Global, and Vista. Customer hospitals reported the bots underdelivered and were difficult to maintain. After multiple layoff rounds in 2022 and 2023, Olive sold its two remaining business units to Waystar and Humata Health in October 2023 and shut down. The brand is gone; the website now serves a single sunset notice.
Reason for Shutdown
Olive sold its remaining product lines in Oct 2023 and wound down operations. CEO Sean Lane confirmed the shutdown publicly.
🩺 Health Signals
No checks have been run on this tool yet.
📅 Timeline
Raises $400M at $4B valuation
https://www.fiercehealthcare.com/tech/olive-raises-400m-valuing-startup-at-4b
Lays off 35% of staff
https://www.cnbc.com/2023/02/14/olive-ai-cuts-35percent-of-staff.html
Sells assets to Waystar and Humata Health; shuts down
https://www.beckershospitalreview.com/healthcare-information-technology/olive-ai-is-shutting-down.html
🔄 Alternatives to Olive AI
ChatGPT
🟢ActiveOpenAI's conversational AI assistant that sparked the generative AI revolution.
Anthropic API
🟢ActiveAPI provider for Claude models, focused on AI safety research.
OpenAI API
🟢ActiveAPI platform providing access to GPT models for developers to build AI applications.
📰 Related Articles
Is Olive AI Still Active in 2026? (Status Explained)
Olive AI, once a prominent player in healthcare AI with a $4 billion valuation, permanently shut down in October 2023. The company sold its remaining business units after customer challenges and multiple layoffs.
8 Best Tools Like Olive AI in 2026 (Healthcare RPA & AI)
Olive AI — the Columbus, Ohio 'AI workforce for healthcare' that reached a $4 billion valuation in 2021 after raising more than $902 million — shut down in October 2023, selling its clearinghouse and patient-access business to Waystar and its Olive Assure utilization-management product to a new company called Humata Health, and stranding hundreds of US health systems mid-contract. Waystar is now the direct RCM heir with Nasdaq scale and Olive's acquired book of business, Notable Health leads AI intake and provider-side prior authorization, Akasa combines RCM RPA with transparent generative AI, Cohere Health owns payer-side prior authorization, Rhyme runs the largest real-time provider-side PA network, UiPath and Automation Anywhere handle horizontal healthcare RPA, and Suki AI covers clinician-facing voice documentation. These eight tools like Olive AI, grouped by revenue cycle, prior authorization, general RPA, and clinical AI and ranked with a rise-and-fall timeline, per-tool pricing, capability matrix, decision tree, and eight-step migration playbook, cover every reason a former Olive customer is searching for a new home in 2026.
🪦 Other dead agents tools
❓ Frequently Asked Questions
What happened to Olive AI?
Olive shut down in October 2023 after burning through more than $900M. It sold two business units to Waystar and Humata Health, then dissolved.
Was Olive's tech actually AI?
Mostly robotic process automation with some ML layered on top. Customers complained the 'AI' was thinner than the marketing implied.
Who bought Olive's customers?
Waystar acquired the prior authorization product; Humata Health acquired the utilization management product.
What killed Olive?
Customer churn, high implementation cost, an overhyped product, and a 2022-23 capital crunch that ended bridge-financing options.